News & Events

Date Title  
02/15/19
SAN DIEGO , Feb. 15, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release
01/03/19
SAN DIEGO , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, promotes Amy VandenBerg to Chief
01/02/19
SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to host a
01/02/19
SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today completed the succession plan
IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click onSafety Information and Patient Labeling